Duration of estrogen deficiency linked to fibrosis risk in NAFLD

Duration of estrogen deficiency linked to fibrosis risk in NAFLD

(HealthDay)—For postmenopausal women with nonalcoholic fatty liver disease (NAFLD), longer duration of estrogen deficiency is associated with increased odds of having more severe fibrosis, according to a study published online Feb. 26 in Hepatology.

Jagpal Singh Klair, M.D., from the University of Arkansas for Medical Sciences in Little Rock, and colleagues examined the of age at menopause and time from menopause with fibrosis severity in postmenopausal women with NAFLD. Data were included for 488 with histologic diagnosis of NAFLD.

The researchers found that women with premature menopause (age at menopause of <40 years) were younger at study enrollment and more frequently used hormone replacement therapy. Premature menopause correlated with increased likelihood of having more severe fibrosis after adjustment for multiple confounding variables, including age at study enrollment, race, and hormone replacement therapy (adjusted cumulative odds ratio, 1.9; P = 0.001). Time from menopause correlated directly with increased likelihood of having more severe fibrosis (adjusted cumulative odds ratio for five-year unit, 1.2; P = 0.002).

"Duration of in postmenopausal state confers fibrosis risk among post-menopausal women with NAFLD," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Hepatology

Copyright © 2016 HealthDay. All rights reserved.

Citation: Duration of estrogen deficiency linked to fibrosis risk in NAFLD (2016, March 21) retrieved 25 April 2024 from https://medicalxpress.com/news/2016-03-duration-estrogen-deficiency-linked-fibrosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Estrogen protects women with NASH from severe liver fibrosis

0 shares

Feedback to editors